

ITOG

2018 ANNUAL MEETING PROGRAM



FRIDAY, APRIL 27TH

10:00 – 5:00 PM **Registration** *Proceed up the right hand stairs* *Luskin Center: 2nd floor*

After 5:00 PM **Registration** *Luskin Center: Front desk*

12:00 – 1:30 PM **Committee Meetings** *Working lunch, pick up box lunch at 2nd floor registration table*

Protocol Committee *Enter through the School of Public Health* *CHS 16-154*

Website & Communications Committee *Take elevator to 2nd floor* *Gonda 2303*

Registry Committee *Take elevator to 3rd floor* *BSRB 301*

1:30 – 6:00 PM **Getty Center Tour** *Sign up available at Registration*

1:30 – 2:00 PM **Board Of Directors Lunch** *Luskin Center: Visionary Room*

2:00 – 5:00 PM **Board Of Directors Meeting** *Luskin Center: Visionary Room*

6:00 – 8:30 PM **Welcome Reception: Evening With Friends And Colleagues** *Luskin Center: Patio*

SATURDAY, APRIL 28TH UCLA FACULTY CENTER

7:00 AM **Registration** *Faculty Center: California Room*

7:00 – 7:30 AM *Breakfast buffet* *Faculty Center: California Room*

7:25 – 7:30 AM **Welcome presented by Wendy Sacks / Andrew Gianoukakis** *Faculty Center: California Room*

SESSION I: BEYOND THE TUMOR IN CANCER RESEARCH *Faculty Center: California Room*

7:30 – 7:50 AM Neural regulation of the cancer genome **Steve Cole**

7:50 – 8:10 AM The microbiome in cancer development, progression and response to therapy **Sandip Patel**

8:10 – 8:30 AM Lifestyle and breast cancer incidence and outcome **Rowan Chlebowski**

SESSION II: ONCO-METABOLISM AND TUMOR MICROENVIRONMENT *Faculty Center: California Room*

8:35 – 8:55 AM Cell extrinsic control of metabolism in cancer **Peter Mullen**

8:55 – 9:15 AM	Mitigating metabolic changes associated with Ras activity and high fat diet in reducing tumor size, lessons from prostate cancer	Neil Bhowmick
9:15 – 9:35 AM	Highly multiplexed imaging of the tumor immune microenvironment	Akil Merchant
9:35 – 9:55 AM	<i>Coffee Break</i>	<i>Faculty Center: California Room</i>
SESSION III: THYROID CANCER GENOMICS AND SIGNALING		<i>Faculty Center: California Room</i>
9:55 – 10:15 AM	Genome evolution in Hurthle cell carcinoma	David McFadden
10:15 – 10:35 AM	Integrated genomic analysis of Hurthle cell carcinoma reveals novel oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes	Ian Ganly
10:35 – 10:55 AM	Discriminating oncogenic states using the OncoGPS analytic framework: applications in thyroid cancer	Bharat Panuganti
10:55 – 11:15 AM	Preclinical models of drug resistance in thyroid cancer	Carmelo Nucera
SESSION IV: MANAGEMENT OF PAPILLARY THYROID MICRO-CARCINOMA: HANDS-OFF?		<i>Faculty Center: California Room</i>
11:20 – 11:40 AM	Management of Papillary Thyroid Micro-carcinoma (PTMC)	Akira Miyauchi
11:40 AM – 12:00 PM	Active surveillance of Thyroid Micro-carcinoma	YongKee Shong
12:00 – 12:20 PM	Proper patient selection for active surveillance of low risk thyroid cancer	Mike Tuttle
12:20 – 12:30 PM	Moderated Panel	Allen Ho
12:30 – 1:00 PM	<i>Lunch</i>	<i>Faculty Center: Terrace</i>
1:00 – 2:00 PM	Group Photo / UCLA Campus Tour	<i>Faculty Center: Outside Entrance</i>
2:15 – 2:45 PM Closed	Annual Business Meeting / Active ITOG Trial Updates ITOG Members Only	<i>Faculty Center: California Room</i>
2:45 PM	All return	<i>Faculty Center: California Room</i>
SESSION V: CHALLENGES IN CANCER TREATMENT		<i>Faculty Center: California Room</i>
2:45 – 3:05 PM	Tumor heterogeneity and resistance	Ravi Salgia
3:05 – 3:25 PM	Response and resistance to PD-1 blockade therapy in cancer	Antoni Ribas
3:25 – 3:30 PM	Gagel Award Introduction	Alan Ho

3:30 – 3:50 PM The role of myeloid-derived suppressor cells in the response to targeted therapies in advanced thyroid cancer Sareh Parengi

SESSION VI: EMERGING CONCEPTS-ANAPLASTIC THYROID CANCER

Faculty Center: California Room

3:55 – 4:10 PM ATC Clinical Trials: Current status of recent, ongoing and planned trials Eric Sherman

4:10 – 4:25 PM Seminal/recent developments in ATC: Tumor mutations, Microenvironment and Immunology Maria Cabanillas

4:25 – 4:40 PM Update on ATC Radiobiology/Radiosensitization Manisha Shah
Closed ITOG Members Only
(Excluding Guests, Industry Partners, and ITOG Members in Industry)

4:40 – 4:50 PM International Rare Cancer Initiative Alan Ho
Closed ITOG Members Only
(Excluding Guests, Industry Partners, and ITOG Members in Industry)

4:50 – 5:15 PM Moderated Panel Discussion David Pfister
Closed ITOG Members Only
(Excluding Guests, Industry Partners, and ITOG Members in Industry)

5:15 - 5:25 PM *Coffee Break* *Faculty Center*

5:25 – 5:45 PM Industry Partner Session

5:25 – 5:35 PM 'Overview of Eisai's Clinical Development - upcoming Investigator initiated Studies with lenvatinib' Prashant Joshi

5:35-5:45 PM Developing Targeted Therapies for Rare Oncogenic Drivers S. Michael Rothenberg

6:30 – 7:15 PM *Reception* *Faculty Center: Terrace*

7:15 – 9:30 PM **Annual ITOG Dinner** *Faculty Center: California Room*
Closed ITOG Members, Spouses, Staff, and Program Speakers Only

Rick Abrams Memorial Lectures:

LA BioMed: A World of Innovation David Meyer

Targeted Therapies in Cancer Medicine: The HER2/neu Story in Breast Cancer Dennis Slamon

Using stem cells to model thyroid hormone cell transporter deficiency in children Clive Svendsen

Passing of the ITOG leadership baton Lori Wirth and Manisha Shah

SUNDAY, APRIL 29TH LUSKIN CONFERENCE CENTER

7:00 – 7:30 AM *Breakfast*

Luskin Center: Laureate Room

SESSION VII: THERAPEUTIC FOREFRONT OF THYROID CANCER

Luskin Center: Laureate Room

7:30 – 7:45 AM Coexisting BRAF V600E and TERT Promoter Mutations: Implications in Thyroid Oncology

MingZhao Xing

7:45 – 8:00 AM Neoadjuvant Vemurafenib for BRAF mutated PTC

Maria Cabanillas

8:00 – 8:15 AM Clinical activity of BLU-667, a highly potent and selective RET inhibitor in advanced, RET-altered thyroid cancer

Mimi Hu

8:15 – 8:30 AM Selective RET inhibition with LOXO-292 in RET-altered Thyroid Cancer Patients

Lori Wirth

Closed **ITOG Members and Guests Only**
(Excluding Industry Partners and ITOG Members in Industry)

8:30 – 8:40 AM *Break*

8:40 – 8:55 AM Phase I/II clinical trials with lenvatinib/pembrolizumab – toxicity and efficacy in non-thyroid solid tumors

Mathew Taylor

8:55 – 9:10 AM MLN0128, a second generation mTOR inhibitor in differentiated and anaplastic thyroid cancer: Update on a phase II study

Jochen Lorch

9:10 – 9:25 AM Genomic insights from a large gene variant and fusion panel

Rick Kloos and Giulia Kennedy

SESSION VIII: FUTURE FOOD FOR THOUGHT

Luskin Center: Laureate Room

9:45 – 10:00 AM Martinique Principles

Victor Bernet

10:00 – 10:15 AM Potential future ITOG-FDA interactions

Mike Menefee

10:15 – 10:30 AM Postsurgical adjuvant treatment with lanreotide in node positive resected medullary thyroid cancer

Mike Demeure

Closed **ITOG Members and Guests Only**
(Excluding Industry Partners and ITOG Members in Industry)

10:30 – 10:45 AM Enhancement of ATF4 expression as a therapeutic strategy for medullary thyroid carcinoma

Robert Gagel

Closed **ITOG Members and Guests Only**
(Excluding Industry Partners and ITOG Members in Industry)

10:45 – 11:00 AM **Discussion**

Luskin Center: Laureate Room

11:00 AM **Closing remarks** by Wendy Sacks and Andrew Gianoukakis

Luskin Center: Laureate Room

11:15 AM *Packed lunch/airport shuttle departure*

SPEAKERS

ITOG MEMBER SPEAKERS

Victor J. Bernet, MD

Chair, Division of Endocrinology, Mayo Clinic – Jacksonville, FL

Maria E. Cabanillas, MD

Associate Professor, MD Anderson Cancer Center

Mike J. Demeure, MD, MBA

Program Director for Precision Medicine, Hoag Family Cancer Center

Bob F. Gagel, MD

Professor, MD Anderson Cancer Center

Andrew G. Gianoukakis, MD

Professor, David Geffen School of Medicine at UCLA, Investigator, Los Angeles Biomedical Research Institute (LA BioMed) at Harbor-UCLA

Alan L. Ho, MD, PhD

Assistant Attending, Memorial Sloan-Kettering Cancer Center

Richard T. Kloos, MD

Senior Medical Director, Veracyte

Jochen H.M. Lorch, MD, MSc

Dana Farber Cancer Institute

David G. McFadden, MD, PhD

Assistant Professor, UT Southwestern Medical Center

Mike Menefee, MD, PhD

Medical Officer, U.S. Food and Drug Administration

Carmelo Nucera, MD, PhD

Assistant Professor, Beth Israel Deaconess Medical Center, Harvard Medical School – Boston, MA

Sareh Parangi, MD

Professor, Massachusetts General Hospital

David G. Pfister, MD

Chief, Head & Neck Medical Oncology, Memorial Sloan-Kettering Cancer Center

Wendy Sacks, MD

Endocrinology, Cedars Sinai Medical Center

Manisha H. Shah, MD

Professor of Internal Medicine, Ohio State University

Eric Sherman, MD

Associate Attending, Memorial Sloan-Kettering Cancer Center

Matthew Taylor, MD

Assistant Professor, Oregon Health and Science University

Michael Tuttle, MD

Clinical Director, Endocrinology, Memorial Sloan-Kettering Cancer Center

Lori J. Wirth, MD

Medical Director, Center for Head & Neck Cancers, Massachusetts General Hospital

Mingzhao Xing, MD, PhD

Professor, Johns Hopkins University

GUEST SPEAKERS

Neil Bhowmick, PhD

Professor, Director, Cancer Biology Program, Cancer Institute, Cedars Sinai Medical Center

Rowan T. Chlebowski, MD, PhD

Professor, Chief, Div. of Medical Oncology/Hematology, Harbor-UCLA Medical Center

Steve Cole PhD

Professor, UCLA School of Medicine

Ian Ganly MD, PhD, MS, FRCS, FRCS-ORL

Associate Professor, Memorial Sloan Kettering Cancer Center

Allen Ho, PhD

Assistant Professor, Co-Director, Thyroid Cancer Program, Cedars-Sinai Medical Center

Mimi Hu, MD

Associate Professor, University of Texas MD Anderson Cancer Center

Giulia C. Kennedy, PhD

Chief Scientific and Medical Officer, Veracyte

Akil Merchant, MD

Assistant Professor, Keck School of Medicine/USC/Norris Cancer Center

David Meyer PhD

Professor, President & Chief Executive Officer, Los Angeles BioMedical Research Institute (LA BioMed) at Harbor-UCLA

Akira Miyauchi, MD

Professor, President and COO, Kuma Hospital, Japan

Peter J. Mullen, PhD

Assistant Project Scientist, UCLA

Sandip P Patel, MD

Assistant Professor, UC San Diego Moores Cancer Center

Bharat Panuganti, MD, PGY-3

Otolaryngology-head and neck Surgery, UC San Diego

Antoni Ribas MD, PhD

Professor, UCLA, Dir. Tumor Immunology, Jonsson Comprehensive Cancer Ctr (JCCC)

Ravi Salgia MD, PhD

Chair in Medical Oncology, City of Hope Medical Center

YoungKee Shong, MD

Professor, Asan Medical Center, Seoul, Korea


Dennis J. Slamon MD, PhD

Professor, Chief, Division of Hematology/Oncology, UCLA, Dir. Revlon/UCLA Women's Cancer Research Program (JCCC)

Clive Svendsen, PhD


Professor, Board of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center

UCLA CAMPUS MAP



UCLA

- P PARKING STRUCTURES
- PARKING LOTS
- CAMPUS BUILDINGS
- CAMPUS ENTRANCES
- CONSTRUCTION AREAS
- i PARKING/INFORMATION KIOSK



THANK YOU TO OUR SPONSORS:

